中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (12): 885-887.doi: 10.12144/zgmfskin202512885

• 病例报告 • 上一篇    下一篇

利妥昔单抗联合甲氨蝶呤治疗窦组织细胞增生伴巨大淋巴结病一例

张晶晶,梁斌,杨颖,闫仟叶,荆琪   

  1. 中国人民解放军空军特色医学中心，北京，100142
  • 出版日期:2025-12-15 发布日期:2025-11-28

Rosai-Dorfman disease successfully treated with rituximab combined with methotrexate: a case report

ZHANG Jingjing, LIANG Bin, YANG Ying, YAN Qianye, JING Qi   

  1. Air Force Medical Center of the People's Liberation Army, Beijing 100142, China
  • Online:2025-12-15 Published:2025-11-28

PDF (PC)

14

摘要： 本文报道一例39岁男性窦组织细胞增生伴巨大淋巴结病（Rosai-Dorfman disease，RDD）患者,予静滴利妥昔单抗500 mg/次，同时给予甲氨蝶呤治疗，第3次利妥昔单抗治疗后面部皮疹大部分消退，躯干部皮疹较前好转，淋巴结缩小。

关键词: 窦组织细胞增生伴巨大淋巴结病, Rosai-Dorfman病, 利妥昔单抗, 甲氨蝶呤, 生物制剂

Abstract: We report a case of a 39-year-old male with sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease, RDD). He was treated with intravenous rituximab at a dose of 500 mg per administration, concurrently with methotrexate. Following the third rituximab infusion, the facial rash had mostly resolved, the truncal rash had improved compared to before, and the lymph nodes had reduced in size.

Key words: sinus histiocytosis with massive lymphadenopathy, Rosai-Dorfman disease, rituximab, methotrexate, biological agents